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Disability pension as predictor of later use of benzodiazepines 
among benzodiazepine users 
Abstract 
The proportion of Norwegians on disability pensions has doubled since the 1980s. The 
Norwegian Government wants action to stimulate the working capacity in those 
disability pensioners who have the potential to work. Information on factors that may 
impair rehabilitation efforts, including the unfavourable use of benzodiazepines, may 
be useful in this context.  A longitudinal design, including data on 40-42 year old 
participants in Norwegian health surveys (year 1985-89) linked to a prescription 
database (year 2004-06), was used to describe risk of  long-term use of 
benzodiazepines among disability pension recipients. The study-population constituted 
benzodiazepine users at baseline. 
More than half of those on disability pensions, 57% of all men and 65% of all women, 
retrieved benzodiazepine prescriptions 20 years later, a span covering a large part of 
the potential active workforce period. Further, the observed amount of 
benzodiazepines dispensed over a three year period indicated more than sporadic use; 
e.g. half of the female disability pensioners were dispensed an amount of 
benzodiazepines corresponding to the use of a daily dose every second day over a 
three year period (median 450 daily doses). The majority of those who was dispensed 
benzodiazepines, was dispensed opioids as well: half of all men and 3 out of four 
women. And last, being on a disability pension was a predictor of benzodiazepine use 
20 years later.  
In conclusion, this prospective study provides new information on the epidemiology of 
benzodiazepine use in disability pensioners. Our study suggests that benzodiazepines 
are extensively and unfavourably used among disability pensioners, and that disability 
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pension may have an independent effect on long-term use. Improved management of 
benzodiazepine use may be one alternative to get disability pensioners with the 
potential to work back into employment. 
 
Key words: disability pension, benzodiazepines, long-term use, longitudinal studies, 
pharmacoepidemiology, prescription database, Norway
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Background 
Norwegians live comparatively long and healthy lives and workforce participation rates 
are very high (NOU, 2007). Still, Norway has a higher percentage of people on disability 
pensions than most other OECD countries (NOU, 2007).  Eleven per cent of the working 
population (18-67 years) received a disability pension in Norway in 2006.
 
The increased number of disability pensioners constitutes both political and economical 
challenges, and the Norwegian Government has urged action to arrest the upward trend of 
people on disability pension.  
When health is poor, being on a disability pension may be a positive alternative to being 
part of the active workforce. However, many disability pensioners feel that their situation 
is passive, unwanted and excludes them from the strong social and personal advantages 
associated with being a part of the workforce (Olsen, Kvåle, & Jentoft, 2005).  In this 
context, efforts to get disability pensioners with the potential to work back into 
employment have been a part of the political agenda for the last decade.  
 
In Norway, and other OECD countries, mental health disorders and musculoskeletal 
problems are the main reasons for claiming disability benefit (NOU, 2007).  
Benzodiazepines have anxiolytic, sedative, anticonvulsant and muscle-relaxant effects, so 
they are likely to be used by disability pensioners to deal with these problems (O'Brien, 
2005). On the other hand, there may be non-medical reasons for use of benzodiazepines 
among disability pensioners, such as explanations related to socio-economic background. 
According to Bourdieu (1979), a person‟s socio-economic background identifies a 
person‟s position in social space, which in turn predisposes for the development of 
certain (habitual) behaviour. The intermediary link between the structural objective 
position and the individual subjective preferences, is the habitus, a set of durable and 
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transposable dispositions. Moreover, people with similar habitus tend to cluster together 
in specific social fields. Thus, based on variables indicating position in social space, 
especially variables related to socio-economic status, one may expect to observe an 
overlap between disability pension and habits of unfavourable use of abusive drugs, such 
as benzodiazepines. This theoretical hypothesis is supported by empirical evidence from 
epidemiological studies which reveal the importance of social, non-medical and 
contextual determinants for being on a disability pension, as well as for the use of 
benzodiazepines (Blennow, Romelsjo, Leifman, Leifman, & Karlsson, 1994; 
Groenewegen, Leufkens, Spreeuwenberg, & Worm, 1999; Krokstad & Westin, 2004). 
 
 
There are concerns about benzodiazepines because of their potential adverse effects, 
which include impaired cognitive function and psychomotor skills, unwanted sedation, as 
well as dependence and abuse problems associated with long-term use (Barker, 
Greenwood, Jackson, & Crowe, 2004; O'Brien, 2005). Because of this, benzodiazepines 
are only recommended for short-term use over a few weeks (Norwegian Board of Health 
Supervision, 2001).  Furthermore, recommendations suggest that combined use with 
other potentially addictive drugs, such as opioids and carisoprodol, should be avoided 
(Norwegian Medicines Agency, 2008). Unfavourable use may be of particular concern in 
disability pensioners, as it adds yet another potential problem to the deterioration of 
people‟s daily functioning.   
 
We need to identify factors that may impair rehabilitation efforts. Within this context, 
information on any unfavourable use of benzodiazepines among disability pensioners 
may be useful. To the best of our knowledge, the epidemiology of drug-taking behaviours 
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in general, and the use of benzodiazepines in particular, among disability pensioners are 
scarcely described in the literature.   
We used a longitudinal design with data on 40-42 years old benzodiazepine users, who 
participated in Norwegian health surveys in 1985-1989, and we linked this information to 
data from a prescription database in 2004-2006. This allows us to describe aspects of use 
of benzodiazepines 20 years after baseline, a span covering a large part of the potential 
active work period.  We described use of benzodiazepines 20 years later according to 
disability pension status at baseline. We also looked at dispensing of opioids and 
carisoprodol to those who were dispensed benzodiazepines. Finally, we evaluated 
disability pension as a predictor of use of benzodiazepines 20 years after baseline.  
 
Material and methods 
Health survey information on independent variables 
The study population comprises attendants in population-based health surveys organised 
by the National Health Screening Service in Norway (The Health Surveys in Østfold 
1985 and 1999 and in Aust-Agder 1986 and 1989). All inhabitants aged 40-42 years at 
the time of screening in the counties Østfold (1985 and 1988) and Aust-Agder (1986 and 
1989) were invited to participate.  The health surveys comprised a medical examination, 
as well as a self-administrated questionnaire covering different socio-demographic, health 
and lifestyle variables such as disability pension status, smoking, physical activity, 
alcohol use, use of analgesics, anxiolytics or hypnotics. Benzodiazepines represented 
99% of all consumption of  anxiolytics/hypnotics in the 1980s in Norway and therefore 
anxiolytic/hypnotic users will be referred to as benzodiazepine users (WHO 
Collaborating Centre for Drug Statistics Methodology, 2006).  
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Altogether 15,606 men and 14,748 women were invited to participate, of whom 7605 
men and 8062 women attended both the medical examination and completed the question 
on use of anxiolytic or hypnotic drugs (response rate 48.7% and 54.7%, respectively). 
Further, we excluded from our study population individuals who died or emigrated from 
Norway (451 men and 326 women) before January 2004 (Figure 1). In a second step, we 
removed all those who received drugs reimbursed for cancer diseases (93 men and 80 
women), as recommendations of short-term use of benzodiazepine in e.g. terminal 
palliative cancer care may apply to this group of patients.  To study the use of 
benzodiazepines after 20 years, we excluded all those who were non-users at baseline. 
Altogether 416 of 7061 men and 1201 of 7656 women were defined as users of 
benzodiazepines at the baseline in 1985-89 according to this definition. These individuals 
were followed up with respect to dispensing of benzodiazepines, opioids and carisoprodol 
in 2004-2006.  
 
In addition to disability status, several other factors at baseline, associated with the use of 
benzodiazepines, were included in our analysis; age, gender, alcohol consumption, 
smoking habits, marital status, physical activity, use of analgesics, and cardiovascular 
morbidity. Details from the questionnaire, from which the variables in our analysis are 
defined, are described elsewhere (Hartz, Lundesgaard, Tverdal, & Skurtveit, 2009). 
 
Norwegian Prescription Database (NorPD) - information on dependent variables 
Prescription data about benzodiazepines in 2004-2006 were taken from the NorPD which 
covers the entire nation (4.6 million inhabitants) (The Norwegian Prescription Database, 
2008).  NorPD contains information of all individuals who have received prescription 
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drugs dispensed at pharmacies, whether these are publicly reimbursed or not. The drugs 
are classified according to the Anatomical Therapeutic Chemical (ATC) classification 
system (WHO Collaborating Centre for Drug Statistics Methodology, 2006). The data 
collected for our study were: patient‟s unique identifying number (encrypted), sex, age, 
the date of dispensing, and drug information (ATC-code, Defined Daily Dose (DDDs)). 
The code of reimbursement is also recorded and this can function as a proxy of diagnosis. 
Code §9.9 is dedicated to cancer diseases.  
 
Prescription drugs are registered at dispensing using ATC classification codes. The 
Benzodiazepines were defined by the ATC-codes N05BA and N05CD, opioids by the 
ATC-code N02A and carisoprodol by the ATC-code M01BA02.  Use was defined when 
an individual was dispensed at least 1 prescription during the study period 1 January 2004 
- 31 December 2006.  In addition, among benzodiazepine users, the amount of 
benzodiazepines dispensed during the same period was calculated in terms of total 
defined daily doses (DDDs).  A DDD in clinical practice is defined as the assumed 
average maintenance dose per day for a drug used on its main indication in adults. 
Data from the health surveys and NorPD were linked on the basis of the unique 11-digit 
identification number, assigned to all individuals living in Norway.  
Statistics  
Chi-square test was used to assess equality of proportions across the groups of drug use. 
Fisher‟s exact test was used when the expected count in cells was less than 5. Mann-
Whitney test was used for variables with a skewed distribution (DDDs).  Odds ratios 
(OR) were estimated with 95 % confidence intervals (CI) for prescriptions of 
benzodiazepines 20 years later. All analyses were done using SPSS 16.0 for Windows. 
Level of significance was set to p<0.05.  
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Ethical considerations 
The study protocol was endorsed by the Regional Committee for Medical Research 
Ethics and the record-linkage was approved by the Norwegian Data Inspectorate. The 
study has been conducted fully in accordance with the World Medical Association 
Declaration of Helsinki.  
Figure 1. Flow chart for the study population. Health surveys in Østfold and Aust-Agder   
(1985-89) 
Responders, men
n=7605
Died or emigrated 
before 2004
n=451
7154
7061
BZD users at baseline
n= 416
- 72 receivers of a DP
- 344 non-receivers of a DP
Non-users of BZDs  at baseline, 
n=6645:
Cancer 
diseases
n=93
Responders, women
n=8062
Died or emigrated 
before 2004
n=326
7736
7656
BZD users at baseline
n= 1201
- 176 receivers of a DP
- 1024 non-receivers of a DP
- 1 missing
Non-users of BZDs at baseline
n=6455
Cancer diseases
n=80
 
 
BZD = benzodiazepine 
DP = Disability pension 
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Results 
Characteristics of the study population at baseline (1985-1989) 
In the subgroup of 40-42 year old individuals who reported using benzodiazepines at 
baseline; 17% (n=72) of all men and 15% (n=176) of all women also reported receiving a 
disability pension (Figure 1). Characteristics of the study population by disability pension 
status are shown in table 1. There was a higher prevalence of unmarried people and 
combined use of analgesic drugs at baseline among those who received a disability 
pension. Further, alcohol habits were different between the groups. Among women, there 
was also a higher prevalence of physically inactive individuals, and individuals with 
cardiovascular history among those on disability pensions. 
 
Dispensing of prescription drugs 20 years later (2004-2006) 
In both genders, the proportion who were dispensed at least one prescription of a 
benzodiazepine 20 years later was significantly higher among those who received a 
disability pension at baseline than those who didn‟t, 57  % versus 40% in men and 65 % 
versus 52% in women (Table 1).  
Among females who were dispensed benzodiazepines 20 years later, opioid prescriptions 
were more commonly dispensed to those who received a disability pension at baseline 
than those who didn‟t, 72% versus 54%, respectively (Table 1).  A smaller non-
significant difference was seen in men. Of those who were dispensed benzodiazepine 20 
years later, fewer were prescribed carisoprodol than opioids (Table 1).   
 
The amount of benzodiazepines dispensed, in terms of median number of daily doses 
during 2004-2006, was significantly higher among females who received disability 
pensions, 450 (interquartile range (IQR) 150,1100) daily doses versus 134 ( 30,569) daily 
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doses in non-receivers. In men, the amount of benzodiazepines dispensed did not differ 
according to disability status; males who received a disability pension were dispensed a 
median amount of 200 (60,885) daily doses compared to 204 (50,700) daily doses among 
the non-receivers.  
 
Factors associated with dispensing of benzodiazepines 20 years later 
After adjustment for lifestyle, health, and socio-economic variables the odds of being 
dispensed benzodiazepine prescriptions 20 years later was 55% higher in those who 
received disability pensions at baseline compared to non-receivers (OR 1.55 (95% CI, 
1.15-2.08)). 
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Table 1.  
Characteristics for benzodiazepine users aged 40–42 years when surveyed in 1985–1989. 
Use of prescription drugs 20 years later retrieved from the Norwegian prescription 
database in 2004–2006. 
 
Men Women 
 
Disability pension (1985–
1989) 
Disability pension (1985–
1989) 
 
Yes 
(N = 72) 
n (%) 
No 
(N = 344) 
n (%) 
p 
Yes 
(N = 176) 
n (%) 
No 
(N = 1024) 
n (%) 
p 
Baseline characteristics 1985–1989 
Alcohol habits 
 Teetotallers 24 (34.3) 38 (11.1) 
 
61 (35.5) 208 (20.7) 
 
 Normal 44 (62.9) 260 (76.2) 
 
107 (62.2) 740 (73.5) 
 
 Problem drinkers 2 (2.9) 43 (12.6) *** 4 (2.3) 59 (5.9) *** 
Smoking habits 
 Current daily smokers 42 (58.3) 172 (50.0) 
 
100 (56.8) 515 (50.3) 
 
 Ex–smokers 18 (25.0) 95 (27.6) 
 
39 (22.2) 242 (23.6) 
 
 Non smokers 12 (16.7) 77 (22.4) n.s. 37 (21.0) 267 (26.1) n.s. 
Seldom/never physically 
active 
26 (36.1) 104 (30.2) n.s 75 (42.6) 296 (28.9) *** 
Unmarried 33 (45.8) 72 (20.9) *** 52 (29.5) 203 (19.8) ** 
Cardiovascular history 16 (22.2) 46 (13.4) n.s 35 (19.9) 91 (8.9) *** 
Analgesic use 37 (51.4) 75 (21.8) *** 103 (58.5) 322 (31.4) *** 
Prescription of drugs in 2004–2006 
Usea of benzodiazepines, 
(%) 
41 (56.9) 138 (40.1) ** 115 (65.3) 537 (52.4) ** 
 of these; % use of opioids 21 (51.2) 66 (47.8) n.s. 83 (72.2) 288 (53.6) *** 
 of these; % use of 
carisoprodol 
7 (17.1) 10 (7.2) n.s. 28 (24.3) 91 (16.9) n.s. 
 of these; % use of 
carisoprodol and opioids 
6 (14.6) 7 (5.1) n.s. 23 (20.0) 68 (12.7) * 
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*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001; n.s., not significant; 
a
 use was 
defined as at least 1 prescription of benzodiazepine (ATC-group N05BA/N05CD) during 
the study period 2004–2006. 
 
 
 
 
Discussion 
In a cohort of 40-42 year olds benzodiazepine users, more than half were dispensed 
benzodiazepine prescriptions 20 later. Being on a disability pension was a predictor of 
benzodiazepine use. Further, the majority of those who were still dispensed 
benzodiazepines, were also dispensed opioids; half of all men and 3 out of four women.  
 
The appropriateness of this benzodiazepine use cannot easily be assessed by measuring 
dispensing 20 years later. One prescription of a benzodiazepine is neither an outcome for 
long-term use, nor an addictive use pattern, and should be interpreted with caution. 
Information on drug use from two measuring points with a 20 year measurement interval, 
could cover individuals with a wide range of use patterns ranging from sporadic to daily 
use. Other studies, however, reveal that having once entered a cohort of benzodiazepine 
use, the probability of still being part of that cohort in the following years is consistently 
high in different populations (Isacson, 1997; Neutel, 2005). 
 Guidelines recommend only short-term use of benzodiazepines, up to 2-4 weeks, and 
they emphasize that combined use with opioids and carisoprodol is especially 
problematic from an addiction point of view (Norwegian Medicines Agency, 2008; 
Norwegian Board of Health Supervision, 2001). These recommendations are obviously 
being violated when dispensing of benzodiazepines and combined use with other 
potentially addictive drugs exists to the extent observed in our study. Use over a span 
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covering a large part of the potential active working period may be especially worrisome 
in disability pensioners, as it can add yet another factor to the deterioration of people‟s 
daily functioning, help consolidate the disability situation.   
 
To the best of our knowledge, no other study has investigated benzodiazepine use in 
general, and among disability pensioners in particular, over such a long period.  
In our study we chose to focus on prescriptions of traditional benzodiazepines, because 
they have well known potential to cause addiction problems and other negative effects 
which interfere with people‟s daily functioning (Barker et al., 2004; O'Brien, 2005).  
Further, the observed amount of benzodiazepines dispensed over a three year period also 
indicates more than sporadic use; e.g. half of the female disability pensioners were 
dispensed an amount of benzodiazepines corresponding to the use of a daily dose every 
second day over a three year period (median 450 daily doses). By comparison, the 
median amount of benzodiazepines dispensed to the average 60 year old benzodiazepine 
user in Norway during the same period was 50 daily doses (IQR 13-230) (The Norwegian 
Prescription Database, 2008). 
 
Among benzodiazepine users at baseline, disability pension predicted dispensing of 
benzodiazepines 20 years later.  So being on a disability pension, as also shown in an 
earlier study, seems to have an impact both on initiation of benzodiazepine use in the first 
place, and on later use (Blennow et al., 1994; Hartz et al., 2009).   
The increased risk of initiation and long-term use of benzodiazepines among disability 
pensioners may, on one hand, be explained by drug use as a proxy of mental illness, the 
precipitating reason for disability in the first place. Obviously, our evaluation of risk-
factors of benzodiazepine use 20 years later has several limitations; even if many 
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potential confounders associated with prescription of benzodiazepines were registered 
and adjusted for in our analysis, not all possible confounders could be taken into account.  
For example, our analysis does not include information on the indication for 
benzodiazepine use in the first place.  
On the other hand, irrespective of the precipitating cause of disability, it is reasonable to 
believe that being in a situation which merits receipt of a disability pension may itself 
bring about a number of psychological problems as a result of exclusion from the social 
and personal advantages associated with being a part of the workforce (Olsen et al., 
2005). Drug treatment with benzodiazepines may be initiated and continued to relieve 
these symptoms. Also, our observation  may be conceived as an overlap between the field 
of disability pension and the field unfavourable use of potentially additive drugs, in line 
with Bourdieu‟s theory of how individuals‟ habitus  relates to people‟s position in social 
space as a predisposition for certain habits which cluster into specific fields (Bourdieu, 
1979). In that respect, the study of the use of potentially addictive drugs in disability 
pensioners adds a contribution to the social science debate about reflexive 
individualization versus determination. Choices – for example related to the initiation as 
well as long-term use of potentially addictive drugs – can therefore be measured if they 
are structured according to classificatory variables. Although new classes are created in 
the reflexive modernity „… the personnel filling these class positions are typically 
determined by more particularistic, “ascribed” characteristics‟ (Lash, 1994, p. 134).  The 
impact of socioeconomic status on the prescribing and use of drugs in general is well 
recognized (Leufkens & Urquhart, 1994). People end up in categories of „winners‟ and 
„losers‟, also today (Lash, 1994, p. 155), dependent on their individual biography – their 
habitus.  
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For investigating receipt of a disability pension as a factor associated with use of 
benzodiazepines 20 years later, a limitation of our study is the description of use of 
benzodiazepines according to self-reported disability status 20 years in the past. The 
proportion of people on a disability pension increases with age; e.g. in 2006 about 25% of 
all men and 37% of all women aged 60 years old in Norway received disability pensions, 
compared to 1-2% of the 40-42 year old participants in our study (NOU, 2007). An 
unknown number of the initially non-disabled 40-42 years old will have changed their 
disability status during this period. If so, the OR estimates as presented will be 
underestimated, and biased towards the null.  
 
 
In conclusion, this prospective study provides new information on the epidemiology of 
benzodiazepine use in disability pensioners. The prospective design of the study gives no 
reason to suspect lack of internal validity of the estimated effects.  Our study suggests 
that benzodiazepines are extensively used among disability pensioners, and that disability 
pension may have an independent effect on long-term use. Efforts to bring those with 
potential to work back into employment have been a part of the political agenda for the 
last decade.  Improved management of benzodiazepine use may need to be one part of 
this effort.  
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